| Date | Title | Description |
| 16.04.2025 | Basilea berichtet über Präsentation neuer Daten zu Fosmanogepix, Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2025 | Allschwil, 16. April 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkr... |
| 16.04.2025 | Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 | Allschwil, Switzerland, April 16, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today sc... |
| 14.03.2025 | Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea | Allschwil, Switzerland, March 14, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today th... |
| 18.02.2025 | Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anstieg von Umsatz, Gewinn und operativem Cashflow | Gesamtumsatz um 32 % auf CHF 209 Mio. gesteigert Betriebsgewinn auf CHF 61 Mio. verdreifacht Operativer Cashflow signifikant auf CHF 74 Mio. erhöht
Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 18. Februar 2025
Basilea Pharmaceutica AG, Al... |
| 18.02.2025 | Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow | Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61m Operating cash flow significantly increased to CHF 74m
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 18, 2025
Basilea Pharmaceutica... |
| 18.02.2025 | Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow | Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61mOperating cash flow significantly increased to CHF 74m
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 18, 2025
Basilea Pharmaceutica ... |
| 05.02.2025 | Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea | Allschwil, Switzerland, February 05, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today ... |
| 28.01.2025 | Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea | Allschwil, Switzerland, January 28, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today t... |
| 16.12.2024 | Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, December 16, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacte... |
| 16.12.2024 | Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, December 16, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacte... |
| 16.12.2024 | Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 16. Dezember 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infe... |
| 10.10.2024 | Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year | Allschwil, Switzerland, October 10, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ... |
| 10.10.2024 | Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus | Allschwil, 10. Oktober 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze er... |
| 24.09.2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| 24.09.2024 | Financial boost for five publicly traded companies |
Altamira Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics for extrahepatic targets, announced the closing of a public offering raising up to $12.0 million. The offering included Series A-1 and Series A-2 com... |
| 19.09.2024 | Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding | Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potential funding of up to approximately USD 26... |
| 06.09.2024 | Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, September 6, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacte... |
| 06.09.2024 | Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, September 6, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacte... |
| 06.09.2024 | Starke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea aus | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 6. September 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infe... |
| 30.08.2024 | US and European approvals open new avenues for Swiss Biotechs |
Life Molecular Imaging (LMI), a partner of AC Immune has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative c... |
| 27.08.2024 | European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, August 27, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteri... |
| 21.08.2024 | Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea | Allschwil, Switzerland, August 21, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today t... |
| 21.08.2024 | Starke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus | Allschwil, 21. August 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erk... |
| 21.08.2024 | Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea | Allschwil, Switzerland, August 21, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today t... |
| 13.08.2024 | Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance | Continued success of Cresemba® with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 million and operating profit guidance in... |
| 20.06.2024 | Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation | Allschwil, Switzerland, June 20, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today tha... |
| 03.05.2024 | Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 | Allschwil, Switzerland, May 03, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that... |
| 03.05.2024 | Basilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024 | Allschwil, 03. Mai 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkran... |
| 23.04.2024 | New report presents good figures from the Swiss biotech sector as high flyers flourish |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is quite positive. In addition to record revenues of CHF 7.3 billion, the industry raised more than CHF 2 billion – a remarkable 50% increase ove... |
| 05.04.2024 | Swiss healthcare innovators tap into the US market |
Basel-based startup Basilea Pharmaceutica announced the FDA approval of ZEVTERA, their antibacterial treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), adult patients with acute bacterial skin and s... |
| 02.04.2024 | A positive growth trajectory for three pharmaceutical startups | Based in Basel, Santhera has pipeline of drugs for neuromuscular and pulmonary diseases that currently lack treatment options. Their drug candidate AGAMREE® (vamorolone) is a first-in-class dissociative steroid with novel mode of action, wh... |
| 11.03.2024 | Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea | - |
| 19.01.2024 | Cresemba®-Verkaufszahlen in Lateinamerika lösen erste Umsatzmeilensteinzahlung an Basilea aus | Allschwil, 19. Januar 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erk... |
| 19.01.2024 | Cresemba® sales in Latin America trigger first sales milestone payment to Basilea | Allschwil, Switzerland, January 19, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ... |
| 15.01.2024 | Basilea announces acquisition of preclinical antibiotics program from Spexis | Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains
Allschwil, Switzerland, January 15, 2024
Basilea Pharmaceutica Ltd, Alls... |
| 15.01.2024 | Basilea acquires Spexis preclinical antibiotics program | |
| 15.01.2024 | Basilea erwirbt präklinisches Antibiotika-Programm von Spexis | Neuartige Antibiotika-Klasse Bakterizide Aktivität (in vitro und in vivo) gegenüber breitem Spektrum gramnegativer Bakterien, einschliesslich multiresistenter Stämme
Allschwil, 15. Januar 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN)... |
| 05.01.2024 | Basilea provides portfolio status update | Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024 Cresemba in-market sales of USD 445 million, increased 22% year-on-year, in 12-month period ending September 2... |
| 05.01.2024 | Basilea gibt Update zum Stand des Portfolios | Wesentliche Stärkung des klinischen Portfolios durch Business-Development-Aktivitäten im Jahr 2023; Beginn von zwei Phase-3-Studien im Jahr 2024 erwartet Steigerung der Cresemba "In-Market"-Umsätze im 12-Monats-Zeitraum bis Septem... |
| 13.11.2023 | Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, November 13, 2023
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacte... |
| 13.11.2023 | Basilea erwirbt Fosmanogepix, ein Phase-3-bereites Breitspektrum-Antipilzmittel | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 13. November 2023
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infe... |
| 15.08.2023 | Basilea reports strong revenue and profit growth in first half-year 2023 | Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9 million and net profit to CHF 31.9 million Increase in cash and restricted cash to CHF 112.9 million Full-ye... |
| 15.08.2023 | Basilea meldet starkes Umsatz- und Gewinnwachstum im ersten Halbjahr 2023 | Anstieg der Einnahmen aus Cresemba® und Zevtera® auf CHF 80.5 Mio. (+57% im Vergleich zum Vorjahreszeitraum) Anstieg des Betriebsgewinns auf CHF 36.9 Mio. und des Konzerngewinns auf CHF 31.9 Mio. Erhöhung der liquiden Mittel und liquiden Mi... |
| 23.03.2023 | Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan | - |
| 23.03.2023 | Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan | – Milestone related to the launch of Cresemba in Japan
Basel/Allschwil, Switzerland, March 23, 2023
Basilea Pharmaceutica Ltd BSLN, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria... |
| 24.01.2023 | Basilea reports preliminary operating profit for 2022, significantly above guidance | Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated
/EIN News/ -- Ad hoc announcement pursuant to Art. 53 LR
Basel/Allschwil, Switzerl... |
| 24.01.2023 | Basilea meldet für 2022 vorläufigen Betriebsgewinn, deutlich über der Guidance | Erfolgreiche Umsetzung der strategischen Entscheidung, sich auf Antiinfektiva zu fokussieren und höher als erwartete Umsätze führen früher als angekündigt zur Profitabilität
/EIN News/ -- Ad hoc-Mitteilung gemäss Art. 53 KR
Basel/Allschwil,... |
| 28.12.2022 | Basilea gibt Rückzahlung von 2022er Wandelanleihe bekannt | /EIN News/ -- Basel/Allschwil, 28. Dezember 2022
Basilea Pharmaceutica AG (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien ode... |
| 28.12.2022 | Basilea announces repayment of 2022 convertible bonds | /EIN News/ -- Basel/Allschwil, Switzerland, December 28, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announ... |
| 23.12.2022 | Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan | Japanese regulatory authority granted marketing authorization to Basilea’s license partner, Asahi Kasei Pharma Intravenous and oral use of Cresemba approved for the treatment of adult patients with aspergillosis, mucormycosis, and cryptococ... |
| 23.12.2022 | Basilea gibt Zulassung für Antimykotikum Cresemba® (Isavuconazol) in Japan bekannt | Japanische Aufsichtsbehörde erteilt Marktzulassung an Basileas Lizenzpartner Asahi Kasei Pharma Zulassung der intravenösen und oralen Darreichungsformen für die Behandlung von erwachsenen Patienten mit Aspergillose, Mukormykose und Kryptoko... |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen | /EIN News/ -- Basel/Allschwil, Switzerland, December 19, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, annou... |
| 19.12.2022 | Basilea erreicht Transfer-Meilenstein für Onkologie-Wirkstoff BAL0891, wodurch USD 4 Mio. Meilensteinzahlung von SillaJen ausgelöst wird | /EIN News/ -- Basel/Allschwil, 19. Dezember 2022
Basilea Pharmaceutica AG (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien ode... |
| 24.10.2022 | ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB) | Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to daptomycin, meeting primary endpoint and demonstrating similar secondary efficacy outcom... |
| 24.10.2022 | ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB) | Late breaker presentation at IDWeek 2022 First double-blind registrational phase 3 study in Staphylococcus aureus bacteremia Ceftobiprole non-inferior to daptomycin, meeting primary endpoint and demonstrating similar secondary efficacy outc... |
| 24.10.2022 | Ergebnisse der Phase-3-Studie ERADICATE unterstreichen die potenzielle Rolle von Ceftobiprol bei der Behandlung von Staphylococcus-aureus-Bakteriämie (SAB) | Late-Breaking-Präsentation an der IDWeek 2022
Erste doppelt verblindete Phase-3-Zulassungsstudie in Staphylococcus-aureus-Bakteriämie
Primärer Endpunkt der Nicht-Unterlegenheit (non-inferiority) von Ceftobiprol gegenüber Daptomycin erreicht... |
| 13.10.2022 | Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022 | First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or without aztreonam
Basel/Allschwil, Switzerland, October 13, 2022
Basilea Pharmaceutica Ltd (SIX... |
| 20.09.2022 | Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance | Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strategic refocusing on anti-infectivesFull-ye... |
| 13.09.2022 | Basilea sells preclinical oncology program for up to CHF242 million | |
| 08.09.2022 | Basilea announces sale of preclinical oncology program to Nodus Oncology | Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF 242 million and approximately 5% participation in net salesImportant step in implementing Basilea’s strategic refocus on anti-infectives
Bas... |
| 07.09.2022 | Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022 | Ad hoc announcement pursuant to Art. 53 LR
Basel/Allschwil, Switzerland, September 07, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial... |
| 16.08.2022 | Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy | CHF 29 million royalty income (+22.5% year-on-year) reflecting continued commercial success of CresembaContinued improvement of operating cash flow CHF 142 million cash, restricted cash and investments at half-year 2022Full-year 2022 guidan... |
| 12.07.2022 | Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil | Basel/Allschwil, Switzerland, July 12, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its distribution partner for Latin America, Knight Therapeutics Inc. (“Knight”, TSX: GUD),... |
| 28.06.2022 | Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) | Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, June 28, 2022
Basilea Pharmaceuti... |
| 27.06.2022 | Basilea reports progress on the implementation of its strategy to focus on anti-infectives | ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortly
Separate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology proj... |
| 24.06.2022 | Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China | Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive... |
| 17.06.2022 | Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer | Basel/Allschwil, Switzerland, June 17, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (... |
| 27.04.2022 | Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center | Basel, Switzerland, April 27, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with bacterial and fungal infections and cancer, announced today that it has ... |
| 13.04.2022 | Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting | Basel, Switzerland, April 13, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinica... |
| 13.04.2022 | Basilea shareholders approve all proposals of the board of directors at the annual general meeting | Press Release
Basel, Switzerland, April 13, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2021.
I... |
| 08.03.2022 | Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress | Press Release
Basel, Switzerland, March 08, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that precli... |
| 15.02.2022 | Basilea to become a leading anti-infectives company backed by strong financial results 2021 | 65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value of oncology assets Sustainable profita... |
| 24.01.2022 | Basilea Pharmaceutica : Updated January 24, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 24, 2022
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibiotic... |
| 24.01.2022 | Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium | Basel, Switzerland, January 24, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that updated interim r... |
| 13.01.2022 | Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China | Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner Pfizer Second approved indication after invasive mucormycosis in December 2021
Basel, Switzerland, January 13, 2022
Basilea P... |
| 11.01.2022 | Basilea Pharmaceutica : Updated January 11, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 11, 2022
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibiotic... |
| 11.01.2022 | Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections | Basel, January 11, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today the completion of patient enrolment... |
| 10.01.2022 | Basilea Pharmaceutica : Updated January 10, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 10, 2022
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibiotic... |
| 10.01.2022 | Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position | Total revenue of CHF 148 million exceeding 2021 financial guidance, driven by 65% increase in non-deferred revenue contributions from Cresemba and Zevtera
CHF 150 million year-end cash and financial investments above 2021 financial guidance... |
| 07.01.2022 | Basilea Pharmaceutica : Updated January 07, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 7, 2022
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibiotic
... |
| 07.01.2022 | Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea | Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, January 07, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and can... |
| 06.01.2022 | Basilea Pharmaceutica : Updated January 06, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 6, 2022
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibiotic
... |
| 06.01.2022 | Basilea reports on portfolio progress made in 2021 | Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin
Basel, January 06, 2022
Basilea ... |
| 22.12.2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba (isavuconazole) in China | Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced that its license partner, Pfizer Inc. (NYSE: PFE, 'Pfizer'), has ... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China | Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba in China to Basilea’s license partner Pfizer
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 21, 2021
Basilea Pharmac... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China | Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba in China to Basilea’s license partner Pfizer
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 21, 2021
Basilea Pharmac... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba(R) (isavuconazole) in China | (MORE TO FOLLOW) Dow Jones Newswires
December 21, 2021 01:15 ET (06:15 GMT) |
| 17.12.2021 | Basilea Pharmaceutica : Updated December 17, 2021 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
December 17, 2021
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibioti... |
| 17.12.2021 | Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891 | Phase 1 study in patients with advanced solid tumors planned to start in the first quarter of 2022
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 17, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage b... |
| 08.12.2021 | Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea | Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 08, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and ca... |
| 16.11.2021 | Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891 | Potential to add third clinical-stage program to oncology pipelineProgressing patient enrolment towards interim analyses in lisavanbulin phase 2 study and in patient cohorts in FIDES-01 and FIDES-02 studies with derazantinib
Basel, Switzerl... |
| 16.11.2021 | Basilea Pharmaceutica : Updated November 16, 2021 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
November 16, 2021
Table of contents
Executive summary
Five reasons to invest
Portfolio
Antifungal
Cresemba® (isavuconazole)
Antibioti... |
| 11.10.2021 | Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference | Basel, Switzerland, October 11, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the presentation of data from preclinical studies demonstrating synergistic anti-tumor effects in a number of gastric cancer models for the combinat... |
| 01.04.2021 | Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary | Basel, Switzerland, April 01, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful closing of the previously announced divestment of its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China... |
| 24.02.2021 | Basilea platziert erfolgreich 1 Million neue Namenaktien und erzielt dabei einen Bruttoerlös von CHF 45.75 Millionen | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
Basel, Schweiz, 24. Februar 2021
Basilea Pharmaceutica AG („Basilea“ oder die „Ges... |
| 24.02.2021 | Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
Basel, Switzerland, February 24, 2021
Basilea Pharmaceutica Ltd. ("Basilea&qu... |
| 23.02.2021 | Basilea launches a private placement of new shares by way of an accelerated bookbuilding | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
Basel, Switzerland, February 23, 2021
Basilea Pharmaceutica Ltd ("Basilea&quo... |
| 16.02.2021 | Basilea meldet für 2020 starke Finanzergebnisse und deutliche Fortschritte in ihrer klinischen Onkologie-Pipeline | Zweistelliges Wachstum der direkt realisierten Umsatzbeiträge durch Cresemba und Zevtera
Betriebsverlust um mehr als 50 % auf CHF 8.2 Mio. verringert
Um 15% verbesserter Cashflow aus operativer Geschäftstätigkeit, zum Jahresende CHF 167 Mio... |
| 16.02.2021 | Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets | Double-digit growth in Cresemba and Zevtera non-deferred revenue contributions
Operating loss reduced by over 50% to CHF 8.2 million
Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments
Established cl... |
| 15.02.2021 | Basilea announces divestment of its Chinese R&D subsidiary to PHT International | Basel, Switzerland, February 15, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”),... |
